The real world evidence of heart failure: A model of epidemiologi | 53500
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

+44 1300 500008

The real world evidence of heart failure: A model of epidemiological research using of administrative big databases

8th Global Cardiologists & Echocardiography Annual Meeting

July 18-20, 2016 Berlin, Germany

Aldo Pietro Maggioni

ANMCO Research Center, Italy

Posters & Accepted Abstracts: J Clin Exp Cardiolog

Abstract :

Aims: Patients with heart failure (HF) randomized in controlled trials are generally selected and do not fully represent the â�?�?real worldâ�?. The purpose of this presentation is to better describe the characteristics of HF analyzing administrative data of a population of nearly 2,500,000 subjects. Methods: Data came from the ARNO Observatory including in-habitants of 5 Local Health Units of the Italian National Health Service (INHS). Patients were selected when discharged for HF (January 1, 2008 - December 31, 2012). Clinical characteristics, pharmacological treatments, rate and reasons for re-hospitalization and direct costs for the INHS occurring during 1 year follow-up (FU) were described. Results: Of the 2,456,739 subjects included in the database, 54,059 (2.2%) were hospitalized for HF: 41,413 were discharged alive and prescribed on HF treatments. Mean age was 78�?±11 years, females accounted for 51.4%. Just 26.6% were managed in a cardiology setting. The more frequent co-morbidities were diabetes (30.7%), COPD (30.5%) and depression (21%). ACEinhibitors/ Angiotensin Receptor Blockers, Beta-Blockers and Mineralocorticoid antagonists were prescribed in 65.8, 49.7 and 42.1% of patients. During 1-year FU at least one re-hospitalization occurred in 56.6% of patients, 49% of them were due to non-cardiovascular causes. INHSâ�?�?s direct cost per patient per year was 11,867â�?¬ of which 76% related to hospitalizations. Conclusions: Real world evidence provides a description of patientsâ�?�? characteristics and treatment patterns that are very different from those reported by randomized clinical trials. Costs for the INHS are mainly driven by hospitalizations which are often due to non-cardiovascular reasons.

Biography :